Business Context and Reporting Period
This Form 8-K is filed by Miragen Therapeutics, Inc. (not Viridian Therapeutics, Inc.) on May 8, 2019. The report serves to disseminate a press release detailing financial results for the three-month period ended March 31, 2019. The company is incorporated in Delaware, trades under the symbol MGEN on the Nasdaq Capital Market, and is classified as an emerging growth company.
Key Financial Metrics
The provided filing text acts as a cover document referencing a press release (Exhibit 99.1) but does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. The filing text does not provide a clear value for any financial metric.
Material Changes
The filing text does not provide specific details on material changes versus the prior comparable period. It only confirms that results for the quarter ended March 31, 2019, were reported in the attached press release.
Guidance, Outlook, and Risks
The filing text does not include management commentary, forward-looking guidance, specific risk factors, or details on contingencies. It explicitly states that the attached press release is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the actual financial figures (revenue, net loss, cash position) by reviewing Exhibit 99.1 (the press release dated May 8, 2019), as they are not present in this 8-K summary text.
- Confirm the company name is Miragen Therapeutics, Inc. (MGEN), noting the discrepancy with the "Viridian Therapeutics" name in the request metadata.
- Check the company's status as an emerging growth company for potential differences in financial reporting standards.
- Review the full press release for any operational updates or pipeline milestones that may not be captured in the 8-K header.